Report period | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
End date of the reporting period | |||||
Capitalization, $ | |||||
Capitalization, $ | |||||
Enterprise Value | |||||
Book Value | |||||
Shareholders Book Value | |||||
Current liabilities | |||||
Noncurrent liabilities | |||||
Total liabilities | |||||
Debt | |||||
Cash and cash equivalents | |||||
Net debt | |||||
Assets | |||||
Total ordinary shares | |||||
Ordinary share price |
Ticker | Name | Type | Nominal value | ISIN | Price |
---|---|---|---|---|---|
OGN:US | Organon & Co. | Common share | - | US68622V1061 | $17.82 |
Company name | Organon & Co. |
---|---|
Tags | #pharmacy, #s&p500 index |
Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals |
Business address | 30 Hudson Street Jersey City, NJ 07302 United States |
Mailing address | 30 Hudson Street Jersey City, NJ 07302 United States |
Website | www.organon.com |
Information disclosure | www.sec.gov |